Lupin’s Ranluspec Biosimilar Launched Across Europe Through Sandoz Partnership

Ranluspec contains ranibizumab, a recombinant humanised monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A (VEGF-A). This protein plays an important role in the formation of blood vessels and is associated with abnormal blood vessel growth and fluid leakage in certain retinal diseases.

Mumbai-headquartered pharmaceutical company Lupin Limited has announced the European launch of Ranluspec, its biosimilar version of ranibizumab, through its commercial partner Sandoz. The company confirmed the development on 12 November 2026, marking an important milestone in its international biosimilars business and expanding the availability of treatments for retinal diseases across European markets, excluding Germany.

The commercial launch follows the European Commission’s approval of Ranluspec in February 2026. The medicine has received regulatory authorisation in both vial and pre-filled syringe presentations, providing treatment options for patients affected by several retinal and choroidal vascular disorders.

Ranluspec was developed, manufactured and registered by Lupin, while Sandoz is responsible for its commercialisation under the companies’ partnership agreement. The launch represents a significant development for Lupin’s biotechnology operations, combining its capabilities in biologic medicine development and manufacturing with Sandoz’s established commercial presence in Europe.

Ranluspec Targets Retinal and Choroidal Vascular Diseases

Ranluspec contains ranibizumab, a recombinant humanised monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A (VEGF-A). This protein plays an important role in the formation of blood vessels and is associated with abnormal blood vessel growth and fluid leakage in certain retinal diseases.

By inhibiting VEGF-A, ranibizumab helps control abnormal vascular activity affecting the retina. The medicine is administered through intravitreal injection, allowing it to act directly within the eye under the supervision of an appropriately qualified healthcare professional.

According to Lupin’s official announcement, Ranluspec is indicated for the treatment of neovascular or wet age-related macular degeneration, diabetic macular oedema, proliferative diabetic retinopathy, macular oedema following retinal vein occlusion and choroidal neovascularisation.

These conditions can cause significant visual impairment because of abnormal blood vessel formation, retinal swelling or leakage of fluid into sensitive structures of the eye. Treatments targeting VEGF-A form an established component of ophthalmic care for patients affected by these disorders.

The availability of Ranluspec introduces another approved biosimilar option for European healthcare providers treating patients with retinal and choroidal vascular diseases.

European Commission Approval Supports Commercial Launch

The European Commission granted marketing authorisation for Ranluspec in February 2026 following an assessment of the evidence submitted to support its quality, safety and efficacy.

Ranluspec is a biosimilar to Lucentis, the reference ranibizumab medicine used in the treatment of retinal diseases. Biosimilars are biological medicines developed to demonstrate high similarity to an already authorised reference product, with no clinically meaningful differences in quality, safety and efficacy.

Unlike conventional chemically synthesised generic medicines, biosimilars are produced through biological manufacturing processes and require extensive analytical and clinical comparability assessments.

Sandoz stated that Ranluspec demonstrated equivalent efficacy and comparable safety to its reference medicine. The European regulatory approval covers the approved indications and provides the foundation for commercial distribution in the relevant markets.

The launch in vial and pre-filled syringe presentations provides healthcare professionals with different authorised delivery formats for use in ophthalmic treatment.

Lupin and Sandoz Partnership Strengthens European Market Presence

The commercial launch follows a partnership announced by Lupin and Sandoz in August 2025 for the supply and commercialisation of a ranibizumab biosimilar.

Under the agreement, Sandoz holds exclusive commercialisation rights for Ranluspec across the European Union, excluding Germany, with semi-exclusive rights in France. Germany is covered by a separate commercial arrangement under which Sandoz markets a ranibizumab biosimilar under the Epruvy brand.

The collaboration combines Lupin’s pharmaceutical development and biologics manufacturing capabilities with Sandoz’s commercial infrastructure and experience in bringing biosimilar medicines to international markets.

For Lupin, the arrangement establishes a commercial channel for its ophthalmology biosimilar in European markets without requiring the company to independently develop a comprehensive distribution network across the region.

The partnership also reflects the growing participation of Indian pharmaceutical companies in international biologics markets, where product development, manufacturing capabilities, regulatory compliance and commercial partnerships are important elements of market entry.

Lupin Highlights Expanding Biosimilars Capabilities

Commenting on the European launch, Thierry Volle, President for Europe, the Middle East, Africa and Emerging Markets at Lupin, said the introduction of Ranluspec advances the company’s strategy of expanding access to high-quality biosimilars for patients affected by retinal and choroidal vascular diseases.

He emphasised the importance of Lupin’s collaboration with Sandoz in supporting the availability of the treatment across European markets.

Dr Cyrus Karkaria, President of Lupin’s Biotech Business, stated that the launch reflected the company’s expanding biosimilars capabilities, bringing together its scientific expertise and biologics manufacturing operations.

The company also highlighted its commitment to addressing unmet medical needs and supporting the sustainability of healthcare systems through the development of biosimilar medicines.

The statements underline Lupin’s emphasis on biotechnology as an important component of its international pharmaceutical business alongside conventional generic formulations and specialised medicines.

Sandoz Expands Ophthalmology Biosimilars Portfolio

The introduction of Ranluspec also strengthens Sandoz’s presence in ophthalmology and adds to its portfolio of biosimilar medicines.

Sandoz has identified biosimilars as a major component of its long-term business strategy, with an ambition to expand its portfolio to more than 100 biosimilars by 2040.

The company has previously introduced biosimilar medicines in several therapeutic areas, including ophthalmology, where biologic treatments play an important role in managing chronic retinal diseases.

The European launch of Ranluspec adds another commercialised treatment to this portfolio and provides an additional option for healthcare systems seeking access to approved biosimilar therapies.

As biological medicines account for an important component of pharmaceutical expenditure in specialised therapeutic areas, biosimilar competition is increasingly relevant to healthcare procurement and medicine accessibility.

Significance for India’s Pharmaceutical and Biotechnology Industry

The European commercialisation of Ranluspec highlights the expanding capabilities of Indian pharmaceutical companies in biologic medicine development and international regulatory compliance.

India has established a substantial presence in global generic pharmaceutical markets, particularly through the manufacture and export of chemically synthesised medicines. The development of biosimilars represents a technologically distinct area involving complex biological manufacturing processes, extensive analytical characterisation and stringent regulatory requirements.

Lupin’s development, manufacturing and registration of Ranluspec demonstrate its participation in this specialised pharmaceutical segment. The European Commission’s approval and subsequent commercial launch through Sandoz establish a concrete international market presence for a biosimilar developed by the Indian company.

The development is particularly relevant to ophthalmology, where biologic treatments targeting VEGF-A are used in managing several retinal diseases that can affect vision.

Lupin operates across branded and generic formulations, complex generics, biotechnology products and active pharmaceutical ingredients, with its medicines distributed in more than 100 markets worldwide.

The European launch of Ranluspec adds another milestone to the company’s international pharmaceutical operations and reflects the increasing role of Indian research and manufacturing capabilities in the global biosimilars industry.

By combining indigenous pharmaceutical development capabilities with international regulatory approval and an established commercial partnership, Lupin has strengthened its participation in the European market for specialised biological medicines while contributing to the wider availability of treatment options for retinal diseases.


Categories